APYX LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Apyx Medical Corporation

June 22, 2022 5:43 PM EDT | Source: Vincent Wong Esq.

New York, New York--(Newsfile Corp. - June 22, 2022) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Apyx Medical Corporation ("Apyx") (NASDAQ: APYX) between May 12, 2021 and March 11, 2022.

If you suffered a loss, contact us at the link below. There is no cost or obligation to you.
https://www.wongesq.com/pslra-1/apyx-medical-corporation-loss-submission-form-2?prid=29014&wire=5

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7094/128655_241150_logo.jpg

Allegations against APYX include that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) a significant number of Apyx's Advanced Energy products were used for off-label indications; (2) such off-label uses led to an increase in the number of medical device reports filed by Apyx reporting serious adverse events; (3) as a result, the Company was reasonably likely to incur regulatory scrutiny; (4) as a result of the foregoing, the Company's financial results would be adversely impacted; and (5) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

If you suffered a loss in Apyx you have until August 5, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/128655

info